P
eripheral artery disease affects >200 million individuals worldwide, and those with exertional leg discomfort, rest pain, and tissue or limb loss have significantly impaired functional status and quality of life. Despite their lower associated risk of repeat revascularization, open surgical procedures have been largely supplanted by endovascular intervention for symptomatic peripheral artery disease given the lower associated morbidity and mortality. 1 Although standalone plain-old percutaneous transluminal angioplasty (PTA) was previously the standard endovascular strategy for these patients, high procedural failure and restenosis rates led to the development of new therapeutic technologies. 2 Stent implantation improved procedural success, 3 and a recent meta-analysis of randomized trials suggests that bare metal stenting (BMS) results in half as much restenosis as PTA. Nevertheless, restenosis after femoropopliteal BMS occurs in up to 37% of patients within 12 months, 4 and observational data suggest that by 5 years, primary patency rates are roughly equivalent (41±4% for BMS versus 36±3% for PTA; P=0.31).
5
Drug-coated balloons (DCBs) were developed as means to further reduce restenosis rates. 6 Currently available DCBs carry the antiproliferative agent paclitaxel, which stabilizes microtubules, preventing mitotic spindle formation and ultimately resulting in reduced neointimal hyperplasia. Paclitaxel doses range from 2 to 3.5 μg/mm 2 of balloon surface area, and carrier molecules ("excipients") facilitate drug delivery to the vessel wall. LEVANT 8 Together, these trial findings suggested that DCBs result in superior short-term outcomes compared with PTA and raised the possibility that higher-dose paclitaxel may be associated with decreased restenosis.
In this issue of Circulation, 2 studies address the efficacy of DCBs to prevent superficial femoral artery restenosis. ILLUMENATE (Prospective, Randomized, Single-Blind, U.S. Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon) was a 294-patient, 18-center, randomized (3:1 DCB versus PTA) study comparing a low-dose paclitaxel DCB with polyethylene glycol excipient (Stellarex, Spectranetics, Colorado Springs, CO) and PTA in patients with Rutherford class 2 to 4 symptoms and >70% de novo or restenotic superficial femoral artery and/or popliteal artery stenosis. 9 Twelve-month primary patency as assessed clinically and by Doppler ultrasound was greater with DCB than PTA (83.9% versus 60.6%; P<0.001). In 33 patients not randomized because they required bailout stenting after predilation, 12-month primary patency was 78.8%. The composite safety end point, freedom from 30-day procedure-related death and 12-month target limb amputation or clinically driven TLR, was superior for DCB compared with PTA (94.1% versus 83.3%; 95% confidence interval, 0.9-23.0), a difference driven by lower TLR (5.9% versus 16.7%; P=0.014). At 12 months, both groups exhibited similar rates of improvement in ankle-brachial index, Rutherford classification, and walking distance, despite the fact that DCB patients required nearly 3-fold fewer TLR procedures. idemia, and tobacco use. Lesion lengths were ≈7 cm, and chronic total occlusions were present in 19% in IL-LUMENATE and 44% to 67% in ISAR-STATH. Procedural technical success was nearly 100% in both studies, although technical success was defined differently (≤50% residual diameter stenosis in ILLUMINATE and <30% in ISAR-STATH). In ILLUMENATE, patients requiring bailout stenting after predilation (n=33) were excluded from randomization and instead were placed in a registry, whereas patients requiring bailout stenting after DCB (n=38) were included in the intention-to-treat analysis. In ISAR-STATH, all PTA and DCB patients received stents, and 14 of 55 patients with atherectomy (25%) underwent bailout stenting; all were included in the intention-to-treat analysis. Both trials encountered issues with follow-up; 89.2% of DCB-randomized patients (198 of 222) and 84.7% of PTA-randomized patients (61 of 72) were available for 12-month follow-up in ILLUMENATE, whereas only 62.5% of DCB plus stent (30 of 48), 80.8% of PTA plus stent (42 of 52), and 80% of patients with atherectomy (44 of 55) underwent 6-month angiography in ISAR-STATH.
What can we learn from ISAR-STATH and ILLUME-NATE? Although we already know that the way in which paclitaxel is delivered to the vessel wall matters (the THUNDER trial [Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries] demonstrated that it is better to coat paclitaxel onto a balloon than simply to place it in the contrast medium 11 ), the ILLU-MENATE findings may argue against a dose-response relationship. In ILLUMENATE, IN.PACT SFA, and LEVANT 2, paclitaxel doses were 2, 3.5, and 2 μg/mm 2 , respectively. Nevertheless, outcomes in ILLUMENATE were similar to those in IN.PACT, and both were superior to LEVANT 2 (Table) . Could these differential trial outcomes be the result of different excipients (polyethylene glycol, urea, and polysorbate/sorbitol, respectively) 12 or of variations in DCB PTA technique (eg, required inflation times in ILLUMENATE, IN.PACT SFA, and LEVANT 2 were >60, >180, and >30 seconds, respectively), or could they simply reflect the different patient populations studied in each of these trials? The ongoing DCB-SFA trial (Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease; NCT02648334), comparing outcomes with Lutonix and IN.PACT balloons head to head, may help answer some of these questions.
There may be much to learn from ISAR-STATH also. Like DEBATE-SFA (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery), which randomized patients to IN.PACT Admiral DCB plus BMS or to PTA plus BMS, 13 ISAR-STATH suggested that DCB plus BMS is associated with less restenosis and lower rates of TLR than the combination of PTA plus BMS (Table) . That atherectomy with bailout stenting did not compare favorably to DCB plus BMS in ISAR-STATH may suggest that atherectomy alone is not a reasonable alternative to using a DCB and BMS in combination.
Like most good trials, these 2 studies raise as many questions as they answer. For example, how would standalone DCB compare to DCB plus BMS? The FAST trial (Femoral Artery Stenting Trial), which compared PTA and PTA plus BMS, found no difference in outcome for lesions <10 cm in length, 14 but data are lacking for longer lesions and for chronic total occlusions. Is standalone DCB as good as PTA plus drug-eluting stent? 15 Is DCB plus drugeluting stent better than DCB and BMS? In addition, would the addition of atherectomy to DCB plus BMS yield patency superior to DCB plus BMS alone? And is all atherectomy created equal? Directional atherectomy, which was used in ISAR-STATH, cuts in a longitudinal plane, but would circumferential plaque removal via rotational, orbital, or laser atherectomy potentially better prepare vessels for subsequent DCB and/or stenting? Last, the role of different devices for different lesion (long, calcified, chronic total occlusion, restenotic) and patient (diabetic, elderly, female) subsets requires further investigation. Remaining questions aside, there is no doubt that these 2 studies move the field another step forward. The investigators are to be congratulated for their important collective efforts.
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